



US009999624B2

(12) **United States Patent**
May et al.

(10) **Patent No.:** **US 9,999,624 B2**
(45) **Date of Patent:** ***Jun. 19, 2018**

(54) **COMBINATION ALZHEIMER THERAPY
USING ANTI-N3PGLU ABETA ANTIBODIES +
A BACE INHIBITOR**

(71) Applicant: **Eli Lilly and Company**, Indianapolis,
IN (US)

(72) Inventors: **Patrick Cornelious May**, Carmel, IN
(US); **Dustin James Mergott**,
Zionsville, IN (US)

(73) Assignee: **Eli Lilly and Company**, Indianapolis,
IN (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days. days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **15/503,027**

(22) PCT Filed: **Sep. 8, 2015**

(86) PCT No.: **PCT/US2015/048807**

§ 371 (c)(1),

(2) Date: **Feb. 10, 2017**

(87) PCT Pub. No.: **WO2016/043997**

PCT Pub. Date: **Mar. 24, 2016**

(65) **Prior Publication Data**

US 2017/0224702 A1 Aug. 10, 2017

Related U.S. Application Data

(60) Provisional application No. 62/050,967, filed on Sep.
16, 2014.

(51) **Int. Cl.**

A61K 39/395 (2006.01)

A61K 31/542 (2006.01)

C07K 16/18 (2006.01)

C07D 513/04 (2006.01)

A61K 45/06 (2006.01)

A61K 39/00 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/542** (2013.01); **A61K 39/3955**
(2013.01); **A61K 45/06** (2013.01); **C07D**
513/04 (2013.01); **C07K 16/18** (2013.01);
A61K 2039/505 (2013.01); **C07K 2317/24**
(2013.01)

(58) **Field of Classification Search**

CPC **A61K 31/542**; **A61K 39/3955**; **A61K**
2039/505; **A61K 45/06**; **C07K 16/18**;
C07D 513/04

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

8,158,620 B2	4/2012	Suzuki et al.
8,278,334 B2	10/2012	Cumming et al.
8,338,407 B2	12/2012	Hall et al.
8,592,408 B2	11/2013	Hall et al.
8,841,293 B1	9/2014	Green et al.
8,940,734 B2	1/2015	Hall et al.
8,961,972 B2	2/2015	Lu et al.
8,987,254 B2	3/2015	Green et al.
2013/0142806 A1 *	6/2013	Lu C07K 16/18
		424/142.1
2014/0275044 A1 *	9/2014	Green A61K 31/542
		514/224.2

OTHER PUBLICATIONS

Jacobsen, et al., "Combined Treatment with a Bace Inhibitor and Anti-A1 Antibody Gantenerumab Enhances Amyloid Reduction in App Mice", *Journal of Neuroscience* 34(35) (2014) pp11621-11630.
May, et al., "Robust Central Reduction of Amyloid- in Humans with an Orally Available, Non-Peptidic -Secretase Inhibitor", *Journal of Neuroscience* 31(46) (2011) pp16507-16516.
Demattos, et al., "Combination Therapy with a Plaque Specific Ao Antibody and Bace Inhibitor Results in Dramatic Plaque Lowering in Aged Pdapp Transgenic Mice", Jul. 16, 2014.
Alzforum, "Anti-Amyloid Therapies Combine Forces to Knock Out Plaques", Jul. 25, 2014.


* cited by examiner

Primary Examiner — Kimberly Ballard

(74) *Attorney, Agent, or Firm* — Nelsen L. Lentz

(57) **ABSTRACT**

The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof; in combination with an effective amount of an anti-N3pGlu Abeta monoclonal antibody.



15 Claims, No Drawings